Doug is a venture partner with over 25 years of experience in the biotechnology industry and over 130 publications in medical journals. He has participated on the boards and SABs of several biotechnology companies including Disarm Therapeutics, Triplet Therapeutics and FAZE Medicines. From 2017 to 2023, he was an integral member of Generation Bio. Joining initially as the head of R&D/CSO and most recently as the Chief Medical Officer. Doug previously ran the neurodevelopmental and neuroscience franchises at Shire, and before that he held senior positions at Biogen where he was the global lead for a series of programs in Alzheimer’s disease, Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA). Doug holds a B.S. from Princeton University and an MD/PhD program from Jefferson Medical College. He completed his neurology residency at Johns Hopkins School of Medicine and served on their faculty for 10 years.